/Biogen%20Inc%20logo%20on%20laptop-by%20monticello%20via%20Shutterstock.jpg)
With a market cap of $26 billion, Biogen Inc. (BIIB) is a global biotechnology company that discovers, develops, and delivers therapies for neurological, autoimmune, and rare diseases across the United States, Europe, and other international markets. Its portfolio includes treatments for conditions such as multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, and various cancers, alongside collaborations with leading pharmaceutical and research organizations.
The Cambridge, Massachusetts-based company is set to unveil its fiscal Q1 2026 results before the market opens on Wednesday, Apr. 29. Ahead of this event, analysts expect BIIB to report an adjusted EPS of $3, down marginally from $3.02 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarters while missing on another occasion.